Clinical Trial Update: A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial evaluating adjuvant intensive therapy in HR+/HER2-negative breast cancer; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: HR+/HER2-breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING